\nRockley Photonics (NYSE: RKLY), a leading global silicon photonics technology company, today announced that the company has expanded the range of possible applications for its non-invasive biomarker sensing technology into new segments of the medical technology field. As part of its long-term strategy to deliver photonics-based solutions for improving healthcare and well-being, Rockley has signed new strategic partnerships with two of the world\u2019s top-ten largest medical equipment and device manufacturers, which together have a combined history of over 200 years in the industry and represent over $40 billion of revenue in the medical equipment market.\n<\/p>\n
\nThese multi-year partnerships will focus on evaluating and incorporating the next generation of non-invasive biomarker sensing in medical equipment and devices in various form factors for different parts of the body and for different medical facilities, such as hospitals and clinics. Rockley expects that these partnerships will also help advance potential use cases of real-time, non-invasive biomarker sensing in mobile devices for outpatient monitoring.\n<\/p>\n
\n\u201cThese new applications and partnerships represent a very exciting opportunity for Rockley. Combining our game-changing sensing technology with our partners\u2019 deep knowledge and experience in developing medical equipment and devices could open doors we haven\u2019t even thought of yet,\u201d said Dr. Andrew Rickman, chief executive officer and founder of Rockley Photonics. \u201cWe believe that extending our technology into a wider variety of devices for both consumers and medtech will bring us one step closer to our vision of giving people better insights into their health and well-being.\u201d\n<\/p>\n
\nRockley\u2019s unique \u201cclinic-on-the-wrist\u201d sensing platform enables device manufacturers to integrate more comprehensive non-invasive biomarker measurements in their products. Rockley\u2019s proprietary photonics-based laser technology significantly expands the range of biomarkers that can be detected and measured by current LED-based sensors. These new measurement capabilities have the potential to transform digital healthcare by providing real-time insights about a variety of health conditions and enabling early detection of multiple disease states.\n<\/p>\n
\nRockley is currently conducting human studies to refine the performance of its end-to-end sensing solution. Once these improvements are completed, Rockley believes that its cloud and artificial intelligence (AI) infrastructure can enable additional capabilities for the fast-growing digital health domain and generate real-time health insights for both patients and health care providers.\n<\/p>\n
\nThe new medtech partners join a growing list of high-profile companies in the consumer and medtech domains that are engaging with Rockley on various development activities, with the common goals of providing actionable insights, transforming digital healthcare, and delivering life-changing benefits to people across the globe.\n<\/p>\n
\nMore information about Rockley\u2019s end-to-end digital health monitoring solution is available here: https:\/\/rockleyphotonics.com\/rockley-unveils-end-to-end-digital-health-monitoring-solution\/<\/a><\/p>\n About Rockley Photonics<\/strong><\/p>\n \nA global leader in silicon photonics, Rockley Photonics (NYSE: RKLY) is developing a comprehensive range of photonic integrated circuits and associated modules, sensors, and full-stack solutions. From next-generation sensing platforms specifically designed for mobile health monitoring and machine vision to high-speed, high-volume solutions for data communications, Rockley is laying the foundation for a new generation of applications across multiple industries. Rockley believes that photonics will eventually become as pervasive as micro-electronics, and it has developed a platform with the power and flexibility needed to address both mass markets and a wide variety of vertical applications.\n<\/p>\n \nFormed in 2013 by Dr. Andrew Rickman (who previously founded the first commercial silicon photonics company, Bookham Technology), Rockley is uniquely positioned to support hyper-scale manufacturing and address a multitude of high-volume markets. Rockley has partnered with numerous Tier-1 customers across a diverse range of industries to deliver the complex optical systems required to bring transformational products to market.\n<\/p>\n \nTo learn more about Rockley, visit rockleyphotonics.com<\/a>.\n<\/p>\n Cautionary Note Regarding Forward-Looking Statements<\/strong><\/p>\n \nStatements in this press release that are not historical facts constitute \u201cforward-looking statements\u201d for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding Rockley\u2019s future expectations, beliefs, plans, objectives, and assumptions regarding future events or performance. The words \u201caccelerate,\u201d \u201cadvance,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cdeveloping,\u201d \u201cenable,\u201d \u201cestimate,\u201d \u201ceventual,\u201d \u201cexpand, \u201cexpect,\u201d \u201cfocus,\u201d \u201cfuture,\u201d \u201cgoal,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201copportunity,\u201d \u201coutlook,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cposition,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201crevolutionize,\u201d \u201cseem,\u201d \u201cshould,\u201d \u201ctrend,\u201d \u201cvision,\u201d \u201cwill,\u201d \u201cwould\u201d or other terms that predict or indicate future events, trends, or expectations, and similar expressions or the negative of such expressions may identify forward-looking statements, but the absence of these words or terms does not mean that a statement is not forward-looking. Forward-looking statements in this press release include, but are not limited to, statements regarding the following: (a) the anticipated benefits of Rockley\u2019s new strategic partnerships, including the potential to: (i) accelerate Rockley\u2019s development of real-time, non-invasive biomarker sensing across a range of uses, such as health condition monitoring and potential early disease detection, (ii) advance potential use cases of real-time, non-invasive biomarker sensing in mobile devices for outpatient monitoring, (iii) open doors to other opportunities, and (iv) bring Rockley closer to its vision of providing people with better insights into their health and well-being; (b) the possible applications of Rockley\u2019s non-invasive biomarker sensing technology in new segments of the medical technology field and to support a wider range of medical equipment and devices; (c) Rockley\u2019s strategy to deliver photonics-based solutions for improving healthcare and well-being; (d) the anticipated focus of these multi-year partnerships on evaluating and incorporating the next generation of non-invasive biomarker sensing in medical equipment and devices in various form factors; (e) the status and potential results of Rockley\u2019s human trials to evaluate and refine the performance of its sensing solution; (f) the ability of Rockley\u2019s cloud and artificial intelligence infrastructure to enable additional capabilities and benefits for the digital health domain; (g) the ability of Rockley\u2019s \u201cclinic-on-the-wrist\u201d technology to enable device manufacturers to integrate more comprehensive non-invasive biomarker measurement in their products; (h) the potential for Rockley\u2019s proprietary photonics-based laser technology to expand the range of biomarkers that can be detected and measured by current LED-based sensors; (i) the potential of such new measurement capabilities to transform digital healthcare by providing real-time insights about a variety of health conditions and enabling early detection of multiple disease states; (j) the potential benefits of Rockley\u2019s engagement with companies in the consumer and medtech domain on various assessment and development activities, with the goal of providing actionable insights, transforming digital healthcare, and delivering life-changing benefits; (k) the anticipated and potential features and benefits of Rockley\u2019s platform, products, and technology; (l) its development of a range of photonic integrated circuits and associated modules, sensors, and full-stack solutions; (m) Rockley\u2019s belief that photonics will eventually become as pervasive as micro-electronics; and (n) Rockley\u2019s potential to support hyper-scale manufacturing, address a multitude of high-volume markets, and deliver the complex optical systems required to bring transformational products to market.\n<\/p>\n \nForward-looking statements are subject to several risks and uncertainties (many of which are beyond Rockley\u2019s control) or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the following: (i) Rockley\u2019s ability to achieve customer acceptance and commercial production of its products and technology, including in a timely and cost-effective manner; (ii) Rockley\u2019s ability to achieve customer design wins and convert memoranda of understanding and development contracts into production contracts; (iii) risks related to purchase orders, including the lack of long-term purchase commitments, the cancellation, reduction, delay, or other changes in customer purchase orders, and if and to the extent customers seek to enter into licensing arrangements in lieu of purchases; (iv) Rockley\u2019s history of losses and need for additional capital and its ability to access additional financing to support its operations and execute on its business plan, as well as the risks associated therewith; (v) legal and regulatory risks; (vi) risks associated with its fabless manufacturing model and dependency on third-party suppliers; (vii) Rockley\u2019s reliance on a few significant customers for a majority of its revenue and its ability to expand and diversify its customer base; (viii) Rockley\u2019s financial performance; (ix) the impacts of COVID-19 on Rockley, its customers and suppliers, its target markets, and the global economy; (x) Rockley\u2019s ability to successfully manage growth and its operations as a public company; (xi) fluctuations in Rockley\u2019s stock price and Rockley\u2019s ability to maintain the listing of its ordinary shares on the NYSE; (xii) Rockley\u2019s ability to anticipate and respond to industry trends and customer requirements; (xiii) changes in the current and future markets in which Rockley is or may be engaged; (xiv) risks related to competition and intellectual property; (xv) market opportunity and demand for Rockley\u2019s products and technology, as well as the customer products into which Rockley\u2019s products and technology are incorporated; (xvi) risks related to international operations; (xvii) risks related to cybersecurity, privacy, and infrastructure; (xviii) risks related to financial and accounting matters; (xix) general economic, financial, political, and business conditions, both domestic and foreign; (xx) Rockley\u2019s ability to realize the anticipated benefits of its recently completed business combination with SC Health Corporation; and (xxi) Rockley\u2019s ability to realize the anticipated benefits of strategic partnerships, as well as other factors described under the heading \u201cRisk Factors\u201d in the prospectus\/proxy statement filed by Rockley on July 22, 2021, Rockley\u2019s quarterly report on Form 10-Q for the quarter ended June 30, 2021, and in other documents Rockley files with the Securities and Exchange Commission in the future.\n<\/p>\n \nThe forward-looking statements contained in this press release are based on various assumptions, whether or not identified in this press release, and on Rockley\u2019s current expectations, beliefs, and assumptions and are not predictions of actual performance. If any of these risks or uncertainties materialize, or should any of these assumptions prove incorrect, actual results may differ materially from those discussed in or implied by these forward-looking statements. There can be no assurance that future developments affecting Rockley will be those that have been anticipated. These forward-looking statements speak only as of the date hereof and Rockley specifically disclaims any obligation to update or revise any forward-looking statements, whether because of new information, future events, or otherwise.\n<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210908006016\/en\/<\/a><\/span><\/p>\n \nMedia KEYWORDS:<\/b> California Europe United States United Kingdom North America<\/p>\n INDUSTRY KEYWORDS:<\/b> Technology Mobile\/Wireless Medical Devices Semiconductor Telecommunications Software Biotechnology Hardware Health<\/p>\n<\/p>\n
\n
Karen Boud
\n
Resonates
\n
Telephone: +44 1635 898 698
\n
Email: rockley@resonates.com<\/a><\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20210908006016\/en\/904031\/3\/20191104_RKLY_Logo_Color_GradBlue_copy_2.jpg\"){kind=logo}
<\/td>\n<\/tr>\n